9 results about "Esophagus Cancers" patented technology

The present invention relates to multispecific antibodies binding to 5T4 and CD3 for use in the treatment of cancer selected from the group consisting of esophageal cancer, Non-small Cell Lung Cancer (NSCLC) and Squamous Cell Carcinoma of the Head and Neck (SCCHN).

The ester derivatives of brefeldin A represented by Formula (I) in the inhibition of tumor proliferation. The compounds are prominent in the prevention or treatment of hyperproliferative diseases, including liver cancer, leukemia, breast cancer, colon adenocarcinoma, gastric cancer, lung cancer, Bart's esophageal cancer, cervical cancer, pancreatic cancer, endometrial cancer, bone cancer, lymphoma, kidney cancer, brain cancer, nerve cancer, nasopharyngeal cancer, oral cancer and colorectal cancer, and have the potential to be developed as antitumor agents.

Provided are a combined therapy of photodynamic therapy and immunological therapy, comprising the combined administration of a porphyrin dimer salt-based photosensitizer and an immune checkpoint inhibitor, and the use thereof in treatment of recurrent and / or metastatic cancers, in particular esophageal cancer.

This invention discloses an esophageal cancer lesion image assessment system, comprising a basic image processing module for generating initial lesion area focus data from input esophageal images; a doctor interaction acquisition module for collecting doctor's correction operations on the initial lesion area focus data; a preference learning module for learning individual preference parameters corresponding to the doctor based on the correction operations; and a personalized output module for calibrating the initial lesion area focus data based on the individual preference parameters and outputting personalized lesion area focus data. This esophageal cancer lesion image assessment system improves the assessment process for esophageal cancer lesions, reducing repetitive correction operations for doctors in handling consecutive cases, decreasing the additional workload as the number of cases increases, and making the initial output more aligned with the doctor's interpretation methods, thereby improving the overall efficiency of the assessment task.

The present disclosure relates generally to compounds of Formulae (1-A), (1-B1), (1-C) and ((1-D) and compositions thereof for inhibition of ErbB2, including mutant forms of ErbB2, particularly those harboring an Exon 20 mutation, methods of preparing said compounds and compositions, and their use in the treatment or prophylaxis of various cancers, such as lung, glioma, skin, head neck, salivary gland, breast, esophageal, liver, stomach (gastric), uterine, cervical, biliary tract, pancreatic, colorectal, renal, bladder, prostate, or ovarian cancer.

The utility model relates to the field of medical instruments, in particular to a nasal esophageal tracheal fistula three-balloon nasal feeding tube composite set loaded with radioactive particles, which comprises a tube body, a lower blocking balloon, a particle balloon, an upper blocking balloon, a tube body butt joint structure and a nasal guide structure. The radion-loaded three-balloon nasal feeding tube composite set for the nasal esophageal and tracheal fistula is a medical instrument which is combined with the nasal feeding tube and can be used for blocking and treating a fistula opening of a patient suffering from the esophageal and esophageal fistula and carrying out precise targeted radiotherapy on a cancerous part of esophageal cancer, and feeding nutrition of the patient is convenient to convey. The device is simple in structure, convenient to operate, high in working and operating efficiency, stable in operation, beneficial to popularization and promotion, capable of effectively relieving pain of patients, convenient to mount and dismount, obvious in acting effect, capable of achieving differentiated treatment, stable in whole and high in pertinence, and has wide market prospects.

Chimeric antigen receptors (CAR) with a binding domain that binds Nectin-4 are disclosed. The Nectin-4 binding domain can be derived from the murine antibody M22-321b41.1. The CAR disclosed herein can be expressed by an immune cell to be used in the treatment of Nectin-4-expressing cancers, such as bladder, breast, ovarian, esophageal, lung, colorectal, or pancreatic cancers.

The invention belongs to the technical field of deep learning and medical image analysis, and particularly relates to a semi-supervised non-negative representation esophageal cancer image clustering method based on a matrix element visual angle, which comprises the following steps: S1, constructing a symmetric similar matrix based on an original matrix, and reconstructing the symmetric similar matrix; S2, constructing an objective function; S3, optimizing the objective function; the invention provides a semi-supervised graph regularization non-negative representation clustering method based on element level analysis. By applying the algorithm to the esophageal cancer image data feature extraction and clustering recognition process, the method achieves the precise clustering division of the image data, improves the nonlinear expression capability and training stability of the model, and improves the accuracy of esophageal cancer image auxiliary diagnosis.

The present application provides a composition for detecting esophageal cancer and use thereof, the composition comprising: a nucleic acid for detecting the methylation state of a target gene, wherein the target gene is one or both of MT1A gene and EPO gene. The present application also provides a kit comprising the composition. And use of the composition in the preparation of a kit for detecting esophageal cancer in vitro.